Franz Humer

Kallyope Appoints Franz Humer, Ph.D., as Chair of its Board of Directors

Retrieved on: 
Tuesday, June 6, 2023
Biotechnology, Neurology, Diabetes, Health, Pharmaceutical, GSK plc, Obesity, University, Therapy, Allianz, International Center, LetterOne, DSM-IV codes, Multimedia, Franz Humer, International Centre for Missing & Exploited Children, University of Innsbruck, Temasek, Gastrointestinal disease, INSEAD, Drug discovery, Diageo, Pharmaceutical industry, Management

View the full release here: https://www.businesswire.com/news/home/20230606005244/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230606005244/en/
    Dr. Humer brings decades of managerial experience to the Kallyope board.
  • He has served as chair of several international companies and currently serves as:
    Member of the board of directors, Allogene Therapeutics
    Member of the board of directors, Emil Frey Holdings
    Member of the board of directors, LetterOne
    “Dr.
  • It is an honor to welcome him to Kallyope as chair of our board of directors,” said Jay Galeota, president and CEO, Kallyope.
  • “I am privileged to join the Kallyope board of directors as chair at this exciting time for the company,” said Dr. Humer.

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Retrieved on: 
Tuesday, October 6, 2020
Professional services, Oncology, Health, Venture capital, Pharmaceutical, Biotechnology, Businesspeople, Franz Humer, Severin Schwan

A world-renowned pharmaceutical industry trailblazer, Dr. Humer served as Chairman and Chief Executive Officer of Roche Holding, Ltd. over a period of 16 years before retiring in 2014.

Key Points: 
  • A world-renowned pharmaceutical industry trailblazer, Dr. Humer served as Chairman and Chief Executive Officer of Roche Holding, Ltd. over a period of 16 years before retiring in 2014.
  • We are honored to welcome Franz as Executive Chairman of our Board of Directors.
  • He was appointed CEO in 1998 and Chairman of the Board of Directors and CEO in April 2001.
  • From March 2008 to March 2014, he served as Chairman of the Board of Directors of Roche Holding Ltd.

TARGET PharmaSolutions Appoints Neal Bibeau Chief Executive Officer

Retrieved on: 
Thursday, February 13, 2020
Franz Humer, Businesspeople, Bibeau

DURHAM, N.C., Feb. 13, 2020 (GLOBE NEWSWIRE) -- TARGET PharmaSolutions (TARGETor the Company), a leading real-world data solutions company for the pharmaceutical and biotech industries, today announced the appointment of Neal Bibeau as Chief Executive Officer, effective immediately.

Key Points: 
  • DURHAM, N.C., Feb. 13, 2020 (GLOBE NEWSWIRE) -- TARGET PharmaSolutions (TARGETor the Company), a leading real-world data solutions company for the pharmaceutical and biotech industries, today announced the appointment of Neal Bibeau as Chief Executive Officer, effective immediately.
  • Meg Powell, PharmD, TARGET Board Chair and Co-Founder, said, Neal Bibeau is a seasoned health care technology executive who has delivered innovative, real-world data solutions for the life sciences industry, driving growth and value for all stakeholders.
  • Neal Bibeau said, I am very excited to be joining TARGET as the Company expands its capabilities to provide healthcare evidence solutions.
  • The Company will also benefit from the appointment of Dr. Franz Humer, the former Chief Executive Officer and Chairman of the Board of Directors of Roche Holding Ltd, as a Senior Advisor.